A powerful clinical tool for appropriate metabolic risk — not a universal longevity drug.
Cost and effort, honestly
What the evidence supports
GLP-1–based medications can produce substantial weight loss, improve glycaemic control and reduce cardiovascular events in certain eligible populations.
Most relevant when
Obesity, type 2 diabetes or related cardiovascular risk meets clinical treatment criteria.
Keep in perspective
Results from high-risk clinical populations should not be generalised to every person seeking longevity. Different medications and doses are not interchangeable.
Safety
Requires physician prescribing and follow-up. Gastrointestinal effects are common; gallbladder complications and other contraindications must be considered. Weight loss should be paired with resistance training and adequate nutrition to protect lean tissue.
Sources
Your payoff
See whether this belongs in your plan, what it could realistically change, and where it ranks against your other options.
- Personal relevance
- Signals it may improve
- Priority versus your alternatives
- Recommended starting point
- How we would track response
Requires your health history, labs and available wearable data.
Educational information, not a diagnosis or prescription. Medication decisions require consultation with a qualified clinician.